Horizon Therapeutics (NASDAQ: HZNP) has seen a 0.6% increase in its stock price as the end date for its $28 billion sale to Amgen was extended until December. The extension, noted in an 8-K filing, pushes the end date to December 12. Approval from the Irish High Court, set for October 5, is the final clearance required for the deal’s closure. Amgen’s CEO, Robert Bradway, anticipates the Horizon deal to be finalized by mid-October, as he mentioned at the Morgan Stanley Global Healthcare conference.
Horizon Therapeutics (NASDAQ:HZNP) ticked up 0.6% after the end date for its planned $28 billion sale to Amgen was extended until December.
The end date was extended to Dec. 12, according to an 8-K filing on Tuesday.
A week ago, Horizon Therapeutics (HZNP) announced that the Irish High Court had set Oct. 5 for a hearing on its planned $28 billion sale to Amgen (NASDAQ:AMGN).
Want to publish your own articles on DistilINFO Publications?
Send us an email, we will get in touch with you.
Approval from the Irish High Court is the last remaining clearance the deal needs before it can close.
Amgen (AMGN) CEO Robert Bradway said he expects the Horizon (HZNP) deal to close by mid October, he commented Tuesday morning at the Morgan Stanley Global Healthcare conference.
Source: NewsBreak